US2012183598A1PendingUtilityA1
Hla-a2 tumor associated antigen peptides and compositions
Est. expiryApr 18, 2023(expired)· nominal 20-yr term from priority
A61P 35/04A61P 35/00A61K 2039/572C07K 7/06A61K 2039/55566A61K 2039/70A61K 39/39A61K 2039/57A61K 2039/55511C07K 14/47A61K 40/4268A61K 40/4266A61K 40/4241A61K 40/4205A61K 40/24A61K 40/19A61K 2239/31A61K 39/0011
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A composition comprising a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope KVFGSLAFV (SEQ ID NO: 7) and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope YLSGADLNL (SEQ ID NO:8), each peptide being less than 15 amino acid residues in length, and the composition further comprising at least three additional peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of
KLBPVQLWV,
(SEQ ID NO: 6)
SMPPPGTRV,
(SEQ ID NO: 5)
IMIGHLVGV,
(SEQ ID NO: 9)
LLTFWNPPV,
(SEQ ID NO: 4)
KVAEIVHFL,
(SEQ ID NO: 10)
RLLQETELV,
(SEQ ID NO: 2)
and
YLQLVFGIEV.
(SEQ ID NO: 3)
16 . A composition of claim 15 , further comprising a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of
KLBPVQLWV,
(SEQ ID NO: 6)
SMPPPGTRV,
(SEQ ID NO: 5)
IMIGHLVGV,
(SEQ ID NO: 9)
LLTFWNPPV,
(SEQ ID NO: 4)
KVAEIVHFL,
(SEQ ID NO: 10)
RLLQETELV,
(SEQ ID NO: 2)
and
YLQLVFGIEV.
(SEQ ID NO: 3)
17 . A composition of claim 16 , further comprising a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of
KLBPVQLWV,
(SEQ ID NO: 6)
SMPPPGTRV,
(SEQ ID NO: 5)
IMIGHLVGV,
(SEQ ID NO: 9)
LLTFWNPPV,
(SEQ ID NO: 4)
KVAEIVHFL,
(SEQ ID NO: 10)
RLLQETELV,
(SEQ ID NO: 2)
and
YLQLVFGIEV.
(SEQ ID NO: 3)
18 . A composition of claim 17 , further comprising a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of
KLBPVQLWV,
(SEQ ID NO: 6)
SMPPPGTRV,
(SEQ ID NO: 5)
IMIGHLVGV,
(SEQ ID NO: 9)
LLTFWNPPV,
(SEQ ID NO: 4)
KVAEIVHFL,
(SEQ ID NO: 10)
RLLQETELV,
(SEQ ID NO: 2)
and
YLQLVFGIEV.
(SEQ ID NO: 3)
19 . A composition of claim 18 , further comprising a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of
KLBPVQLWV,
(SEQ ID NO: 6)
SMPPPGTRV,
(SEQ ID NO: 5)
IMIGHLVGV,
(SEQ ID NO: 9)
LLTFWNPPV,
(SEQ ID NO: 4)
KVAEIVHFL,
(SEQ ID NO: 10)
RLLQETELV,
(SEQ ID NO: 2)
and
YLQLVFGIEV.
(SEQ ID NO: 3)
20 . A composition according to claim 15 , further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises a helper T lymphocyte (HTL) epitope.
21 . A composition according to claim 20 , wherein said additional peptide is a pan-DR binding peptide.
22 . A composition according to claim 21 , wherein said pan-DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).
23 . A composition according to claim 15 , further comprising a liposome.
24 . A composition according to claim 15 , further comprising a lipid.
25 . A composition according to claim 15 , further comprising a pharmaceutical excipient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.